Rare Disease Discussions podcast

Kidney Involvement in Lysosomal Disorders

0:00
1:00:00
15 Sekunden vorwärts
15 Sekunden vorwärts
Ozlem Goker-Alpan, MD, Founder and President, LDRTC and David G. Warnock, MD. Professor of Medicine (Emeritus) at University of Alabama at Birmingham discuss best practices to identify and treat kidney problems associated with lysosomal disorders.

This CME/CE activity describes the pathophysiologies and management options for lysosomal disease patients with kidney problems. This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.

To receive credit for this program, go to https://checkrare.com/learning/

Speakers
Ozlem Goker-Alpan, MD, Founder and President, LDRTC
David G. Warnock, MD. Professor of Medicine (Emeritus)
University of Alabama at Birmingham

Disclosures
AffinityCE staff, LDRTC staff, CheckRare staff, planners, and reviewers, have no relevant financial interests to disclose. All faculty disclosures are listed below and are included in the beginning of each presentation.
Dr. Goker-Alpan is a consultant, a principal investigator and /or on the speaker bureau, or has received grant support, from the following pharmaceutical companies: Actelion, Amicus Therapeutics, Sanofi, Takeda, Pfizer/Protalix.
Dr. Warnock has had research support and/or consulting arrangements with Genzyme Corporation (Sanofi), Shire LLC (Takeda), Amicus, Protalix and Chiesi, Zebra Bio, Walking Fish, Hanmi, and Vera Therapeutics.

Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.


  • Learning Objectives
  • At the end of this activity, participants should be able to:
  • Describe the role of the nephrologist in the team approach to care
  • Describe best practices to monitor kidney function in lysosomal disorders
  • Describe best practices to treat kidney disorders lysosomal disorders

Support for this educational activity was provided by Takeda, Sanofi, Amicus Therapeutics and Chiesi USA.

Weitere Episoden von „Rare Disease Discussions“